AMR containment in Thailand

Slides:



Advertisements
Similar presentations
World Health Day 2011.
Advertisements

RATIONAL USE OF INJECTION: An Integrated Tool For Monitoring Injection Prescription in the Kingdom of CAMBODIA Dr Sok Srun Department of Hospitals, MoH.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Combatting Antimicrobial Drug Resistance Dr Charles Penn Pandemic and Epidemic Diseases Health Security and Environment.
| Antimicrobial Resistance Global Report on Surveillance 2014 Global Action Plan to combat antimicrobial resistance.
Multidrug resistant organisms: What are we up against? Hans Jørn Kolmos MD DMSc Professor, consultant Department of Clinical Microbiology Odense University.
CHOICE OF ANTIBIOTICS IN THE VIEW OF DEVELOPING ANTIBIOTIC RESISTANCE Dr. Jolanta Miciulevičienė Vilnius City Clinical Hospital National Public Health.
PAHO Pan American Health Organization Pan American Sanitary Bureau Regional Office for the Americas for the World Health Organization.
World Health Day 2011: Antimicrobial Resistance 1 |1 | Prevention and Containment of Antimicrobial Resistance USE ANTIBIOTICS RATIONALLY.
Antimicrobial Stewardship
A mixed model to promote rational use of medicines Nithima Sumpradit (1,2); Pisonthi Chongtrakul (3); Kunyada Anuwong (4); Somying Pumtong (4) 1: Food.
ECDC-EMEA Joint Technical Report Part I: Trends and burden of antimicrobial resistance in the European Union Zsuzsanna Jakab, Director European Centre.
Abstract ID: 395 Author Name: Araya Sripairoj Presenter Name: Araya Sripairoj Authors: Sripairoj A, Liamputtong P, Harvey K.
English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Figures Slideset.
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Ministerial Declaration and Concluding Remarks MD PhD Karin Tegmark Wisell Chair AMR expert group, NDPHS.
Antibiotic resistance: National actions contribute to a global solution NEPAL Professor Paras K Pokharel Vice Chair GARP Nepal.
Országos Epidemiológiai Központ National Center for Epidemiology, Budapest, Hungary Activities in Hungary for preventing AMR and controlling HCAI Emese.
Northern Dimension Antibiotic Resistance Study NoDARS Prof Jaana Vuopio, M.D., Ph.D., PAC 11 side-event, 19 November 2015, Berlin, Germany.
Antibiotic-resistant Bacteria
Antibiotics: handle with care!
Antibiotics – Friend and enemy (or revenge of the microbes).
Country presentations Thailand Dr
Introduction to Antimicrobial Resistance
Dr.Mowna Karthick M.D MICROBIOLOGY
EARS-Net data on Antimicrobial Resistance in Ireland, Q
Antimicrobial Resistance (AMR)
Somali Federal Republic Ministry of Health
WHO Medicines Work in Countries: The Kenya Example
Pharmacy and Therapeutics Committees in Thai Hospitals under Health Reform Sripairoj A, Liamputtong P, Harvey K La Trobe University, Australia.
Infection Control in the ICU
Professor Alan Johnson Department of HCAI & AMR
Stevce Acevski PhD Alkaloid AD ISPOR Macedonia
Antibiotics: handle with care!
ECDC-EMEA Joint Technical Report Part I: Trends and burden of antimicrobial resistance in the European Union Zsuzsanna Jakab, Director European Centre.
Antimicrobial Resistance in Hospitals: Lack of Effective Treatment for Gram Negative Bacilli and the Rise of Resistant Clostridium difficile Infections.
Declaration of the 11th ministerial-level PAC meeting in Berlin 2015 From strategies to action – how to tackle the challenges of Antimicrobial Resistance.
E. Monee’ Carter-Griffin DNP, RN, ACNP-BC
Summary of WHO PPL, CDC, and ESKAPE pathogen lists
Antimicrobial Resistance: Plans for Korea and Beyond
Chapter 1: Introduction to Multidrug – Resistant Organisms
The challenges of multi-drug-resistance in hepatology
Antimicrobial Resistance: from Global to Local
Antibiotic Resistance: Strategic Solutions
CNISP & CIHI MRSA infection rate comparison Preliminary results
Promoting Socioeconomic Transformation in ASEAN
Antibiotic Resistance
Empirical antibiotic treatment algorithm for hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP). Empirical antibiotic treatment algorithm.
Summary of WHO PPL, CDC, and ESKAPE pathogen lists
Is the prevalence of antibiotic-resistant organisms changing in Canadian hospitals? Comparison of point-prevalence survey results in 2010 and 2012  V.
Ayman A. Hussein et al. JACEP 2016;2:
Appropriate vs. inappropriate antimicrobial therapy
A multicentre analysis of epidemiology of the nosocomial bloodstream infections in Japanese university hospitals  M. Nagao  Clinical Microbiology and.
Quantamatrix Multiplexed Assay Platform system for direct detection of bacteria and antibiotic resistance determinants in positive blood culture bottles 
Essential Drugs and Medicines Policy
World Health Day 2011.
Strategies for managing today's infections
Essential Drugs and Medicines Policy
Evolving problems with resistant pathogens
Test 3 Flash Cards.
E. Tacconelli  Clinical Microbiology and Infection 
Point prevalence survey (PPS) of healthcare associated infections (HAI) & antimicrobial use (AMU) in acute care Mark McConaghy, Dr Muhammad Sartaj,
Антибиотикийн тэсвэржилт- дэлхий нийтийн тулгамдсан асуудал
Antibiotic overconsumption and resistance in Turkey
Healthy Tourism: challenges in program and research at destinations
EARS-Net results 2011 Ole Heuer
Impact of a targeted isolation strategy at intensive-care-unit-admission on intensive- care-unit-acquired infection related to multidrug-resistant bacteria:
EARS-Net data on Antimicrobial Resistance in Ireland, Q
Antibiotics: handle with care!
A pathway to policy commitment for sustainability of a key population-led health services model in Thailand Dr. Preecha Prempree Deputy Director-General,
Presentation transcript:

AMR containment in Thailand Dr. Phusit Prakongsai Bureau of International Health Ministry of Public Health, Thailand GHSA meeting, Bangkok. 6-8 May 2015

Outline A brief background on AMR burden & situation of antibiotic consumption Containment measures & results Conclusion & challenges The way forward

Magnitude of AMR burden Population ~ 64 millions Health burden (based on data in 2010) AMR infections ~ 88,000 cases Mortality due to AMR infections ~ 38,000 cases Economic burden Antibiotic use for AMR treatment ~ 200 million USD Indirect costs due to AMR > 1 billion USD Phumart P, et al. Health and Economic Impacts of Antimicrobial Resistant Infections in Thailand : A Preliminary Study. Journal of Health Systems Research. 2012;6:352-60.

Important resistant bacteria Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae e.g., K. pneumoniae & E. coli Acinetobacter spp., and Pseudomonas aeruginosa in hospital settings especially ICU Multi-drug resistance Staphylococcus เช่น Methicillin-resistant S. aureus (MRSA) and Methicillin-resistant S. coagulase-negative staphylococci (MRCoNS) Carbapenem resistant Enterobacteriaceae (CRE) e.g., NDM-1 Vancomycin-resistant enterococci (VRE) MDR-TB, XDR-TB etc.

Antibiotic consumption Year Total drug consumption (Million USD) Antibiotics 2009 3,600 370 2012 5,400 570 Three antibiotics with highest consumption costs: Penicillins, Cephalosporins and Carbapenems (2009) Note: Proxy from the values of antibiotic production and importation Source: Thai FDA

AMR containment measures Multi-level: Global, Regional, National and Local Multi-faceted: Education, Regulation, Incentive and Management Mutli-sectoral: Human, animal, and non-human sectors

Global & Regional policies on AMR National policies related to AMR GHSA, GAP-AMR, Jaipur Declaration, ASEAN Post-2015 National policies related to AMR National Drug Policy and strategies 2012-2016 Rational use of medicine strategy Antimicrobial resistance National Strategies on EID 2013-2016 One Health Approach

National level (Implementation) AMR surveillance Infection control program and committee Regulation: Antibiotic reclassification (Rx drugs, in process) Prohibition of antibiotics as growth promoter Incentive & Administrative: P4P policy by NHSO Hospital accreditation Pharmacy accreditation Education: Curriculum revision of health professionals inc. vet Horizontal structure: 10 committees, 8 sub-committees Vertical structure: DDC, DMSc, FDA, DLD, …

Programs/Projects/Partnerships Healthcare setting/Community / Farm Antibiotic Smart Use project (2007) AMR containment program (2012) RDU hospital project (2014) Public campaign & network strengthening by CSO (2010) Healthcare setting/Community / Farm (Targets of change & implementation) Hospitals & Clinics Pharmacies Communities

Results Population-based data are limited. The available data are the rates of antibiotic prescription in out-patient department for URI and acute diarrhea. Data from IPD, pharmacy and community are scattered.

Rate of antibiotic prescription in URI (2012 – 2015) 53.6% 40.2% 60 50 40 30 20 10 % antibiotic prescription 2015_Mar 2015_Feb 2015_Jan 2014_Q4 2014_Q3 2014_Q2 2014_Q1 2013_Q2 2013_Q1 2012_Q2 Example of the implementation of P4P policy of NHSO. Data from 892 hospitals. Data sources: 892 hospitals; OP VISIT = 344,054,775 VISIT; DIAG_URI = 25,299,389 VISIT; ATB USED = 12,373,774 VISIT Source: National Health Security Office (Trithape Fongthong, 2015)

Conclusions Availability of stakeholders, agencies, projects and programs on AMR containment Availability of laws, regulations and policies Availability of evidence (domestic & international) to support AMR containment

Challenges Need for collaborating mechanisms and action plans among AMR stakeholders Lack of population-based data on antimicrobial use Unawareness of AMR problems Need policy/political support

The ways forward Photo from: http://www.irishchamberorchestra.com/press/press-releases/ We are singing but we sing different songs. So, we need the melody notes that all can sing along together! Melody notes = National Action Plan on AMR (Integrated) Conductors = Political leadership & Coordination structure Keep practicing = Long walk together toward the shared goal